Novo Nordisk's best-selling diabetes drug expected to have soared in Q3
Ozempic, a diabetes treatment, will have seen an 80% sales growth in the year’s third quarter compared to the same time last year, according to estimates collected by the pharmaceutical firm itself.
.jpg)
by marketwire, translated by daniel pedersen
As Novo Nordisk is having trouble keeping up with demand for its obesity medicine, Wegovy, sales of diabetes type 2 treatment Ozempic are flying high. In the second quarter alone, the drug surpassed sales of DKK 14bn (USD 1.9bn), which was around DKK 1bn (USD 133m) over analysts’ expectations.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
.jpg)
Novo Nordisk supplier gets another FDA warning
For subscribers
